Referencias
- Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid. 2002;12:889-896.
- Carling T, Udelsman R: Thyroid tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. Vols. 1 & 2. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2008, pp 1663-82.
- Pacini F, Vorontsova T, Molinaro E, et al.: Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 352 (9130): 763-6, 1998.
- Tronko MD, Howe GR, Bogdanova TI, et al.: A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst 98 (13): 897-903, 2006.
- Iribarren C, Haselkorn T, Tekawa IS, et al.: Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93 (5): 745-50, 2001.
- Ferrer García JC, Merino Torres JF, Ponce Marco JL, Piñón Sellés F. Metástasis poco habituales del carcinoma diferenciado de tiroides. An Med Interna (Madrid) 2002; 19: 579-582.
- Cano Valdez, Aspectos Histológicos del Cáncer Diferenciado de la Tiroides. Cancerología 4 (2009): 73-83
- Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511–518.
- Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9:421-427.
- Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996;172:692-4.
- Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998; 138:249-252.
- Duren, M., Siperstein, A.E., Shen, W., Duh, Q.Y., Morita, E., Clark, O.H.: Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 126:13, 1999
- Lind P, Kumnig M, Heinisch I, Mikosch P, Gallwitsch ... Iodine supplementation in Austria: methods and results.Thyroid 2002;12:903-907
- Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endo- crinol Metab Clin North Am. 1996;25:93-113.
- Lubin E, Mechlis-Frish S, Zatz S, Shimoni A, Segal K, Avra- ham A, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metasta- tic differentiated thyroid carcinoma. J Nucl Med. 1994;35:257- 62.
- Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-619
- Hard G. C. Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ. Health Perspect., 106: 427-436, 1998
- Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man. Mutation Res. 1995;333:123–129.
- Merck Manual of Medical Information website. Available at: http://www.merck.com/mrkshared/mmanual_home/contents.jsp . Accessed March 25, 2003. Consultado 2011
- Defining cancer. National Cancer Institute website. Available at: http://www.cancer.gov/cancertopics/what-is-cancer . Accessed August 1, 2008. Consultado 2011.
- Detailed guide. American Cancer Society website. Available at: http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=72 . Accessed August 1, 2008. Consultado 2011.
- Fuster V, Ross R, Topol EJ. Aterosclerosis y enfermedad arterial coronaria. Springer Science & Business, 1997, pp. 434.
- Darmell J. Lodish H, Baltimore D. Molecular cell biology. New York: Freeman; 1986:987-1035.
- Robbins y Cotran Patología estructural y funcional compendio 7a ediion, Elsevier, 2007. Pág. 170, 180.
- Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Par- mentier C. Detection and treatment of lung metastases of diffe- rentiated thyroid carcinoma in patients with normal chest x- rays. J Nucl Med. 1988;29:1790-4.
- Black EG, Cassoni A, Gimlette TM, Harmer CL, Maisey MN, Oates GD, et al. Serum thyroglobulin in thyroid cancer. Lancet. 1981;2:443-5.
- Grant S, Luttrell B, Reeve T, Wiseman J, Wilmshurst E, Stiel J, et al. Thyroglobulin may be undetectable in the serum of pa- tients with metastatic disease secondary to differentiated thy- roid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer. 1984;54:1625-8.
- Hamburger JI, Miler JM, Kini SR. Lymphoma of the thyroid. Ann Intern Med 1993; 99:685-693.
- Rosai J, Carcangiu ML, Delellis RA. Tumors of the thyroid gland. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathol- ogy. Vol 5. Washington, DC: Armed Forces Institute of Pa- thology; 1992:161–182.
- Rosai J. Poorly differentiated carcinomas of the thyroid: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol. 2004;15:293–296.
- Xavier Matias-Guiu, José Cameselle-Teijeiro Clasificación de la OMS de cáncer de tiroides (2004)
- Akslen LA, Livolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyr- oid carcinoma. Cancer. 2000;88:1902–1908.
- Sakamoto A. Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience. Endocr Pathol. 2004;15:307–311.
- Lazar V, Bidart JM, Caillou B, y col. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999 Sep;84(9):3228-34
- Schönberger J, Rüschoff J, Grimm D, y col.Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002 Sep;12(9):747-54.
- Matsuzu K, Segade F, Matsuzu U, y col.. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004 Oct;14(10):806-12
- Hooft L, van der Veldt AA, van Diest PJ, y col. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab. 2005 Jan;90(1):328-34
- Matsuzu K, Segade F, Wong M, y col.. Glucose transporters in the thyroid. Thyroid. 2005 Jun;15(6):545-50
- Maier A, T Asano, Volker A, E Boles, Fuhrmann GF (2002). "Caracterización del transporte de glucosa en Saccharomyces cerevisiae con vesículas de membrana plasmática (contratransporte) y células intactas (la captación inicial) con un solo Hxt1, Hxt2, Hxt3, Hxt4, Hxt6, Hxt7 o GAL2 transportistas" La investigación FEMS levadura 2 (4):. 539 - . 550 DOI : 10.1111/j.1567-1364.2002.tb00121.x . PMID 12702270 .
- Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:485-60.
- Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339-45.
- Bagchi N, Fawcett DM. Role of sodium ion in active transport of iodide by cultured thyroid cells. Biochim Biophys Acta. 1973 Aug 22;318(2):235–251
- Carrasco N. Iodide transport in the thyroid gland . Biochim Biophys Acta 1993; 1154:65-82.
- Eskyari S, Loo DD, Dai G, Levy O, Wright EM, y Carrasco N Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J Biol Chem 1997; 272: 27230- 27238.
- Filetti S, Bidart J-M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/ iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–457.
- Brown-Grant K Extra thyroidal iodide concentrating mechanisms. Physiol Rev 1961; 41: 189-213
- De la Vieja, Dohán, Ginter et al.LA SAGA DEL TRANSPORTADOR DE YODURO (NIS): DE SU IDENTIFICACIÓN MOLECULAR A SU PAPEL CLÍNICO EN EL CÁNCER. Mensaje Bioquímico, Vol XXVI. Depto Bioquímica, Fac Me- dicina, Universidad Nacional Autónoma de México. Cd Universitaria, México, DF, MÉXICO. (2002).
- Schmutzler C, Winzer R, Meissner-Weigl J & Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in non transformed FRTL-5 rat thyroid cells. Biochemical and Biophysical Research Communications 1997 240 832–838.
- Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL & Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997 138 3555–3558.
- Arturi F, Russo D, Schlumberger M, DuVillard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG & Filetti S. Iodide symporter gene expression in human thyroid tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 2493 – 2496.
- Schmutzler C & Kohrle J. Implications of the molecular characterization of the sodium–iodide symporter (NIS). Experi- mental and Clinical Endocrinology and Diabetes 1998 106 (Suppl 3) S1–S9.
- Min JJ, Chung JK, Lee Y, Jeong J, Lee D, Jang J, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imag 2001;28:639-45.
- Mian C, Barollo S, Pennelli G, Pavan N, Rugge M. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol 2008;68:108-16.
- Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroidcarcinoma. Thyroid. 2000;10:211–217. –
- Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 2000;143:623-7.